Liposomal-encapsulated chemotherapy: Preliminary results of a phase I study of a novel liposomal paclitaxel

ONCOLOGY

Volumn 15, Issue 5 SUPPL. 7, 2001, Pages 44-48

  Treat, Joseph ^a,b   Damjanov, Nevena ^b   Huang, Cho ^b   Zrada, Steven ^c   Rahman, Aquilar ^d  

^a Department of Medical Oncology ^*  (United States)

^b TEMPLE UNIVERSITY HEALTH SYSTEM   (United States)

^c THOMAS JEFFERSON UNIVERSITY   (United States)

^d NeoPharm   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOTOXIN; PACLITAXEL;

BREAST TUMOR; DRUG DELIVERY SYSTEM; FEMALE; HUMAN; METHODOLOGY; MULTIDRUG RESISTANCE; OVARY TUMOR; PHASE 1 CLINICAL TRIAL; REVIEW;

BREAST NEOPLASMS; CLINICAL TRIALS, PHASE I; CYTOTOXINS; DRUG DELIVERY SYSTEMS; DRUG RESISTANCE, MULTIPLE; FEMALE; HUMANS; OVARIAN NEOPLASMS; PACLITAXEL;

EID: 0035345231     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Bangham AD, Standish MM, Watkins JC: Diffusion of univalent ions across the lamellae of swollen phospholipids. J Mol Biol 13:238-252, 1965.
2. Gregoriadis G: Targeting of drugs. Nature 265:407-411, 1977.
3. Gabizon A, Price DC, Huberty J, et al: Effect of liposome composition and other factors on the targeting of liposomes to experimental tumors: Biodistribution and imaging studies. Cancer Res 50:6371-6378, 1990.
4. Allen TM, Hansen C: Pharmacokinetics of stealth versus conventional liposomes: Effect of dose. Biochim Biophys Acta 1068:133-141, 1991.
5. Allen TM, Hansen C, Martin F, et al: Liposomes containing synthetic lipid derivatives of poly(ethylen glycol) show prolonged circulation half-lives in vivo. Biochim Biophys Acta 1066:29-36, 1991.
6. Gabizon A, Papahadjopoulos D: The role of surface charge and hydrophilic groups on liposome clearance in vivo. Biochim Biophys Acta 1103:94-100, 1992.
7. Woodle MC, Matthay KK, Newman MS, et al: Versatility in lipid compositions showing prolonged circulation with sterically stabilized liposomes. Biochim Biophys Acta 1105:193-200, 1992.
8. Ahl PL, Bhatia SK, Meers P, et al: Enhancement of the in vivo circulation lifetime of L-a-distearoylphsphatidylcholine liposomes: Importance of liposomal aggregation versus complement opsonization. Biochim Biophys Acta 1329:370-382, 1997.
9. Needham D, Zhelev DV, McIntosh TJ: Surface chemistry of the sterically stabilized PEG liposome, in Janoff AS (ed): Liposomes: Rational Design, pp 13-62. New York, Marcel Dekker Inc, 1999.
10. Hwang KJ: Liposome Pharmacokinetics, in Ostro MJ (ed): Liposomes: From Biophysics to Therapeutics. New York, Marcel Dekker Inc, 1987.
11. Papahadjopoulos D, Allen TM, Gabizon A: Sterically stabilized liposomes: Improvements in pharmacokinetics and antitumor therapeutic efficacy. Proc Natl Acad Sci USA 88:11460-11464, 1991.
12. Allen TM, Hansen CB, Lopes de Menezes DE: Pharmacokinetics of long-circulating liposomes. Adv Drug Del Rev 16:267-284, 1995.
13. Allen TM, Stuart DD: Liposome pharmacokinetics. Classical, sterically-stabilized, cationic liposomes and immunoliposomes, in Janoff AS (ed): Liposomes: Rational Design, pp 63-87. New York, Marcel Dekker Inc, 1999.
14. Rahman A, Treat J, Roh HK, et al: A Phase I clinical trial and pharmacokinetic evaluation of liposome-encapsulated doxorubicin. J Clin Oncol 8:1093-1100, 1990.
15. Gabizon A, Amselem S, Goren D, et al: Preclinical and clinical experience with doxorubicin-liposome preparation. J Liposome Res 1:491-502, 1990.
16. Perez-Soler R, Lopez-Bercstein G, Lautersztain J, et al: Phase I clinical and pharmacological study of liposome-entrapped cis-bis-neodecanoato-trans-R, R-1,2-diaminocy-clohexane platinum (II). Cancer Res 50:4254-4259, 1990.
17. Pestalozzi B, Schwendener R, Sauter C, et al: Phase I/II study of liposome-complexed mitoxantrone in patients with advanced breast cancer. Ann Oncol 3(6):445-449, 1992.
18. Gill PS, Espina BM, Muggia F, et al: Phase I/II clinical pharmacokinetic evaluation of liposomal daunorubicin. J Clin Oncol 13(4): 996-1003, 1995.
19. Newman MS, Colbern GT, Working PK, et al: Comparative pharmacokinetics, tissue distribution, and therapeutic effectiveness of cisplatin encapsulated in long-circulating, pegylated liposomes (SPI-077) in tumor-bearing mice. Cancer Chemother Pharmacol 43:1-7, 1999.
20. Papahadjopoulos D, Gabizon AA: Sterically stabilized (Stealth) liposomes. Pharmacological properties and drug carrying potential in cancer, in Philippot JR and Schuber F (eds): Liposomes as Tools in Basic Research and Industry, pp 177-188. Boca Raton, FL, CRC Press, 1995.